Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer

This publication has 29 references indexed in Scilit:

• Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer
  JNCI Journal of the National Cancer Institute, 2009
• Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients
  British Journal of Cancer, 2008
• Development and validation of a predictive model for chemotherapy-associated thrombosis
  Blood, 2008
• Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
  JAMA, 2008
• Weighing the Hazards of Erythropoiesis Stimulation in Patients with Cancer
  New England Journal of Medicine, 2007
• Erythropoietin, the FDA, and Oncology
  New England Journal of Medicine, 2007
• EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
  European Journal Of Cancer, 2007
• The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
  Journal of Pain and Symptom Management, 2004
• Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives
  Journal of Clinical Epidemiology, 1993
• A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  Journal of Chronic Diseases, 1987